Bold claim: Gene-edited CAR-T cells offer new hope for aggressive T-cell leukemia, expanding options where conventional therapies fall short. But here's where it gets controversial: can a one-size-fits-all, off-the-shelf therapy truly replace traditional, patient-specific approaches yet? This rewritten piece preserves the essential details of the original—while presenting them with clearer explanations and slightly expanded context to help beginners grasp the science and its significance.
A team from University College London (UCL) and Great Ormond Street Hospital (GOSH) has developed a pioneering treatment for T-cell acute lymphoblastic leukemia (T-ALL), a fast-progressing and relatively rare blood cancer. The therapy uses genome-edited immune cells designed to target T-ALL in patients who often have limited treatment choices. This first-in-kind approach is called BE-CAR7 and relies on a precise form of genome editing that changes individual DNA letters inside living cells without broad cuts to the genome.
Base editing, a refined evolution of CRISPR technology, alters single DNA letters with high precision. This enables the creation of universal or "off-the-shelf" CAR-T cells that can be given to different patients and still effectively recognize and attack T-cell leukemia.
A landmark moment came in 2022 when researchers treated Alyssa, a 13-year-old from Leicester, using base-edited therapy—the world’s first such treatment in a patient. Since then, BE-CAR7 has been administered to eight more children and two adults across GOSH and King’s College Hospital (KCH).
Clinical trial results, published in the New England Journal of Medicine and presented at the 67th American Society of Hematology Annual Meeting, show promising outcomes:
- About 82% of patients achieved very deep remission after BE-CAR7 treatment, enabling them to proceed to a stem-cell transplant with no detectable disease.
- Roughly 64% remained free of leukemia, and the earliest recipients have been disease-free and off therapy for up to three years.
- Manageable side effects included low blood counts, cytokine release syndrome, and rashes; the most serious risks were related to infections while the immune system rebuilt.
How CAR-T therapy works in this context
CAR-T cell immunotherapy modifies a patient’s T-cells to express a Chimeric Antigen Receptor (CAR) that helps the cells identify and kill cancerous cells bearing specific markers. Developing CAR-T therapies for leukemias arising from T-cells has been particularly challenging because the treatment must destroy malignant T-cells without triggering the engineered cells to attack themselves.
What makes BE-CAR7 different: universal, base-edited CAR T-cells
BE-CAR7 uses a next-generation genome-editing method that avoids cutting DNA, reducing the risk of chromosomal damage. By changing single DNA letters, researchers reprogram the cells and create banked, universal CAR T-cells that can be used across patients while still targeting CD7-positive leukemia.
In this study, universal CAR T-cells were sourced from healthy donors’ white blood cells. Engineering occurred in GOSH’s clean room using a combination of custom RNA, mRNA, and a lentiviral vector within an automated system. Key steps included:
- Removing native receptors so donor cells can be stored and given to any patient without a perfect match, creating truly universal T-cells.
- Eliminating the CD7 marker, which identifies T-cells, to prevent the engineered cells from attacking each other—avoiding a phenomenon known as “friendly fire.”
- Removing CD52 to prevent a common antibody-based therapy from eradicating the engineered cells.
- Inserting a CAR that detects CD7 on leukemic T-cells, with additional DNA instructions delivered by a disabled virus to empower the cells to locate and attack CD7-positive leukemia.
From cancer clearance to immune system rebuilding
Once delivered, BE-CAR7 T-cells rapidly hunt down and destroy T-cells throughout the body, including malignant ones. If leukemia is cleared within the first month, patients typically undergo a bone marrow transplant to restore a healthy immune system over the ensuing months.
Expert insights
Professor Waseem Qasim, who led the research and serves as a professor of cell and gene therapy at UCL and an honorary consultant immunologist at GOSH, notes that universal, base-edited CAR-T cells have demonstrated activity against stubborn CD7+ leukemia. He also emphasizes the collaborative effort across hospitals and universities and acknowledges that while many patients benefit, some do not—and these treatments remain intense and complex for families.
Dr. Rob Chiesa, a study investigator at GOSH, remarks that while most children with T-cell leukemia respond to standard therapies, about 20% do not. For these patients, BE-CAR7 represents a meaningful new option, offering hope for a better prognosis. He highlights the teamwork behind patient success, spanning bone marrow transplant teams, hematology, ward staff, educators, and researchers.
Dr. Deborah Yallop of King’s College Hospital adds that the responses seen so far—especially clearing previously incurable leukemia—underscore the therapy’s potential when conventional options fail.
Funding and expanded access
The trial is sponsored by GOSH and supported by the Medical Research Council, Wellcome, and the NIHR. NHS patients who are eligible can discuss participation with their healthcare teams. GOSH Charity has pledged funds to support treatment for an additional 10 T-ALL patients, amounting to over £2 million in support to broaden access and contribute to a fundraising campaign for a new Children’s Cancer Centre dedicated to advancing cutting-edge research.
Alyssa’s ongoing resilience
Alyssa Tapley, now 16, became the world’s first recipient of a base-edited cell therapy. Her leukemia became undetectable, and she has since moved into long-term follow-up and resumed a full, active life with friends. Her journey—from initial diagnosis in May 2021 after prolonged viral-like illnesses to enduring chemotherapy and a first bone marrow transplant that didn’t work—illustrates the transformative potential and personal challenges of this research. Alyssa’s message to participants is hopeful: she participated to help others, and her outcomes have validated that choice. She now pursues personal goals, including driving and potentially a career in research.
Infrastructure, collaboration, and the road ahead
BE-CAR7 cells were produced through a long-running research program at the UCL Great Ormond Street Institute of Child Health, led by Professor Qasim. Support from NIHR, Wellcome, the MRC, and GOSH Charity enabled the development of this innovative genome-editing therapy. The team now operates from the Zayed Centre for Research into Rare Disease in Children, established through a substantial donation to support this kind of work.
Acknowledgments
Researchers express gratitude to Anthony Nolan, stem cell donors, patients, and families who contributed to this work, which continues to push the boundaries of cancer treatment and immune rebuilding.
